AbCellera Biologics Inc (ABCL) Stock is Just Right Size-Neither Too Big Nor Too Small

The Benchmark Company raised the price target for the AbCellera Biologics Inc (NASDAQ:ABCL) stock from “a Hold” to “a Buy”. The rating was released on February 22, 2024, according to finviz. The stock was resumed by Piper Sandler, who disclosed in a research note on October 13, 2023, to Overweight and set the price objective to $20.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.17 during the last quarter as opposed to a consensus estimate of -$0.13, which indicates the company missed its estimate by -$0.04, which implies that the company surprised the market by -30.80%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.16. This is an average of 8 analysts’ earnings, where the high earnings per share estimate is -$0.12 and the low earnings per share estimate is -$0.25. According to 8 analyst estimates, an average revenue estimate of $11.02M is projected for the current quarter with a high revenue estimate of $18.29M and a low estimate of $8.9M.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -3.27% within the last five trades and -12.08% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -4.72% in the last 6 months and -25.13% was subtracted to its value over the previous 3 months. ABCL stock is trading at a margin of -6.21%, -11.07% and -17.67% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, ABCL deals in the Healthcare domain. The stock is trading -44.84 percent below its 52-week high and 14.73 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -36.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does AbCellera Biologics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -623.80 percent and the profit margin is -384.99 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $1.30 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 34.18 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.12, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 29.92 percent of AbCellera Biologics Inc shares are owned by insiders, and 38.38 percent are held by financial institutions. Thermopylae Holdings Ltd., the 10% Owner at AbCellera Biologics Inc (ABCL) has bought 153,000 shares of firm on May 26 ’23 at a price of $6.52 against the total amount of $1.0 million. In another inside trade, Booth Andrew, Chief Financial Officer of AbCellera Biologics Inc (NASDAQ:ABCL) bought 14,500 shares of the firm on May 26 ’23 for a total worth of $99325.0 at a price of $6.85.

Most Popular

Related Posts